{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-25-012921","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.729455+00:00","generated_at":"2026-05-16T21:53:24.105078+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Tenax Therapeutics Q3 net loss $15.8M; Phase 3 LEVEL enrollment on track","bullets":["Net loss of $15.8M for Q3 2025 vs $4.0M in Q3 2024; R&D expenses $10.3M (up from $3.1M).","Cash and cash equivalents $99.4M as of Sept 30, 2025; expected to fund operations through 2027.","Phase 3 LEVEL study (TNX-103) targeting 230 patients; enrollment completion expected H1 2026, topline data H2 2026.","On track to initiate second Phase 3 study LEVEL-2 in 2025; 160+ global sites qualified.","European Patent Office intends to grant patent for levosimendan in PH-HFpEF, extending IP to Dec 2040."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-25-012921","json":"https://secwatch.observer/filing/0001654954-25-012921.json","markdown":"https://secwatch.observer/filing/0001654954-25-012921.md","text":"https://secwatch.observer/filing/0001654954-25-012921.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495425012921/0001654954-25-012921-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495425012921/tennx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:53:24.105078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}